B. Riley Predicts Abacus Life's Q4 Earnings (NASDAQ:ABL)

Key Points

• B. Riley has downgraded its Q4 2025 earnings estimate for Abacus Life to $0.18 per share from $0.20, reflecting a cautious outlook on the company's performance.
• Despite the downgrade, several brokerages maintain a positive stance on Abacus Life, with a current consensus rating of "Buy" and a price target averaging $13.70.
• Abacus Life's stock recently traded at $6.36 and reported revenues of $56.23 million in the latest quarter, exceeding the consensus estimate of $43.38 million.

Abacus Life, Inc. (NASDAQ:ABL - Free Report) - Investment analysts at B. Riley cut their Q4 2025 EPS estimates for Abacus Life in a report issued on Wednesday, August 13th. B. Riley analyst R. Binner now anticipates that the company will earn $0.18 per share for the quarter, down from their previous estimate of $0.20. The consensus estimate for Abacus Life's current full-year earnings is $0.62 per share.

Abacus Life (NASDAQ:ABL - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.16 by $0.06. The firm had revenue of $56.23 million for the quarter, compared to analyst estimates of $43.38 million. Abacus Life had a positive return on equity of 17.65% and a negative net margin of 0.72%.

A number of other equities research analysts have also recently issued reports on the stock. Maxim Group assumed coverage on shares of Abacus Life in a research note on Tuesday, April 29th. They issued a "buy" rating and a $14.00 price objective for the company. Piper Sandler cut their price target on shares of Abacus Life from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, July 2nd. Finally, Wall Street Zen raised Abacus Life from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $13.70.

Abacus Life Price Performance

NASDAQ ABL traded up $0.1760 on Thursday, reaching $6.5260. 184,789 shares of the company's stock traded hands, compared to its average volume of 602,650. The stock has a market cap of $632.04 million, a PE ratio of -109.08 and a beta of 0.01. Abacus Life has a 12 month low of $4.60 and a 12 month high of $11.00. The stock has a 50-day simple moving average of $5.50 and a 200 day simple moving average of $6.96. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.76 and a quick ratio of 0.76.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. AlphaQuest LLC purchased a new position in shares of Abacus Life in the 2nd quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in shares of Abacus Life during the 2nd quarter valued at $27,000. Raymond James Financial Inc. bought a new position in shares of Abacus Life during the second quarter valued at approximately $34,000. Legal & General Group Plc purchased a new position in shares of Abacus Life during the second quarter valued at approximately $34,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Abacus Life in the 2nd quarter worth approximately $41,000.

Abacus Life Company Profile

Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.